The emergence of checkpoint inhibitors (ICIs), specifically monoclonal antibodies targeting programmed cell death 1 (PD-1) and its ligand (PD-L1), has revolutionized the therapeutic landscape for advanced non-small cell lung cancer (NSCLC) in cases without targetable driver mutations [1]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.